Value of acute-phase reactants in monitoring disease activity and treatment response in idiopathic retroperitoneal fibrosis

Prospective evaluation of the value of erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels in monitoring disease activity and treatment response in patients with idiopathic retroperitoneal fibrosis (RPF). This study included 57 patients with idiopathic RPF receiving tamoxifen mo...

Full description

Saved in:
Bibliographic Details
Published in:Nephrology, dialysis, transplantation dialysis, transplantation, 2012-07, Vol.27 (7), p.2819-2825
Main Authors: PELKMANS, Lindsey G, AARNOUDSE, Albert-Jan L. H, HENDRIKSZ, Tadek R, BOMMEL, Eric F. H. Van
Format: Article
Language:English
Subjects:
Acute-Phase Proteins - analysis
Aged
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Biological and medical sciences
Blood Sedimentation
C-Reactive Protein - analysis
Disease Progression
Emergency and intensive care: renal failure. Dialysis management
Female
Follow-Up Studies
Humans
Intensive care medicine
Kaplan-Meier Estimate
Male
Medical sciences
Middle Aged
Nephrology. Urinary tract diseases
Nephropathies. Renovascular diseases. Renal failure
Prognosis
Prospective Studies
Renal failure
Retroperitoneal Fibrosis - diagnosis
Retroperitoneal Fibrosis - drug therapy
Retroperitoneal Fibrosis - mortality
Risk Factors
Survival Rate
Tamoxifen - therapeutic use
Tomography, X-Ray Computed
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Prospective evaluation of the value of erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels in monitoring disease activity and treatment response in patients with idiopathic retroperitoneal fibrosis (RPF). This study included 57 patients with idiopathic RPF receiving tamoxifen monotherapy with at least 8 months follow-up. Clinical, laboratory and radiological investigation was performed at presentation and at repeated follow-up. Remission was defined as significant clinical improvement within 6 weeks of treatment together with stable or decreasing mass size on follow-up computed tomography (CT) scanning at 4 months and definitive decrease in mass size on follow-up CT scanning at 8 months. ESR and CRP levels at presentation and their respective decreases over time correlated strongly with each other (P
ISSN:0931-0509
1460-2385
DOI:10.1093/ndt/gfr779